Genmab — Juli 2017

[dohk]

ser ikke ud til Pd1 inhibitorer får en plads en i behandling af MM

[Helge_LarsenPI-redaktør]

God morgen.

[bibob]

God morgen.

[JKY_VH]

God morgen:-)

[E_L]

Celgene Corporation Enters Into Global Strategic Immuno-Oncology Collaboration with BeiGene to Advance PD-1 Inhibitor Program for Solid Tumor Cancers http://ir.celgene.com/releasedetail.cfm?ReleaseID=1032240

[GeorgeBest]

Nature Publication Reports Favorable Clinical Trial Results of BioNTech's Individualized Cancer Vaccine IVAC MUTANOME http://www.4-traders.com/news/Nature-Publication-Reports-Favorable-Clinical-Trial-Results-of-BioNTech-s-Individualized-Cancer-Vacc--24703913/

[bibob]

That doesn't have anything to doo with Genmab, - has it. ?? E L.

[E_L]

no, not directly, just wanted to show there are still plenty companies thinking PD1 inhibitor
is usefull

[Bulder]

Vi har vel heller ikke hørt dårligt (endnu) om nivolumab, som kører i et kombistudie med dara i bl.a. MM?

[Bulder]

Kunne det tænkes at problemet ligger specifikt i Keytruda?

[E_L]

sure, or or maybe even Keytruda in that specific combo only. time will tell.

[Jedi]

I agree. The current problems of Keytruda are limited to MM. All Keytruda trials outside MM continue at full speed and PD-1 / PD-L1 agents are still considered very successful in solid tumors

[Jedi]

The new Celgene collaboration on PD-1 is also targeting solid tumors and not MM

[Bulder]

Ingen tvivl om at PD-1 kører ufortrødent videre i solide tumorer. Så må vi vente og se om Opdivo (sammen med dara) giver problemer i MM.

[Jedi]

Det kunne jo også være kombinationen af PD-1 og en Imid (Revlimid/Pomalyst) som giver en uheldig bivirkning i MM, mens Dara + PD-1 virker ok, det kan vi håbe på - det bliver spændende at følge

[E_L]

NICE : Daratumumab with lenalidomide and dexamethasone for treating relapsed or refractory multiple myeloma (terminated appraisal) Technology appraisal [TA454] Published date: 05 July 2017
https://www.nice.org.uk/guidance/ta454

[E_L]

this is as expected, Janssen had withdrawn this application

[E_L]

we wati for this Daratumumab for multiple myeloma [ID933] In development [GID-TA10076] Expected publication date: 26 July 2017

[E_L]

but there is a negative advice for that one as we know, so small chance only that they´ll approve

[E_L]

you have to love this italian title - daratumumab, "killer seriale"
lol https://www.pharmastar.it/news/italia/mieloma-multiplo-disponibile-anche-in-italia-daratumumab-killer-seriale-delle-cellule-tumorali--24458